Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
June 25, 2026
Undergraduate Student Perspectives on Medicinal Chemistry and Drug Discovery Research
David E Heppner, Ignat S Fomin, Uriy V Grabovyy, et al.
Cancer Research
|
January 24, 2024
TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, et al.
Nature Communications
|
October 31, 2018
Direct cysteine sulfenylation drives activation of the Src kinase
David E Heppner, Christopher M Dustin, Chenyi Liao, et al.
JCI Insight
|
November 5, 2016
DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma
Aida Habibovic, Milena Hristova, David E Heppner, et al.
Nature Communications
|
May 9, 2022
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
Tyler S Beyett, Ciric To, David E Heppner, et al.
Redox Biology
|
February 9, 2019
Lung epithelial protein disulfide isomerase A3 (PDIA3) plays an important role in influenza infection, inflammation, and airway mechanics
Nicolas Chamberlain, Bethany R Korwin-Mihavics, Emily M Nakada, et al.
Scientific Reports
|
March 21, 2019
Dysregulated Redox Regulation Contributes to Nuclear EGFR Localization and Pathogenicity in Lung Cancer
Andrew C Little, Milena Hristova, Loes van Lith, et al.
Journal of Medicinal Chemistry
|
June 20, 2025
Enhancing Selectivity and Potency of S<sub>N</sub>Ar Covalent Inhibitors of NADPH Oxidase Enzymes
Blessing C Ogboo, Kishan B Patel, Marta Massari, et al.
ACS Medicinal Chemistry Letters
|
November 22, 2019
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors
Dries J H De Clercq, David E Heppner, Ciric To, et al.
ACS Medicinal Chemistry Letters
|
December 15, 2022
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
David E Heppner, Florian Wittlinger, Tyler S Beyett, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
June 25, 2026
Undergraduate Student Perspectives on Medicinal Chemistry and Drug Discovery Research
David E Heppner, Ignat S Fomin, Uriy V Grabovyy, et al.
Cancer Research
|
January 24, 2024
TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, et al.
Nature Communications
|
October 31, 2018
Direct cysteine sulfenylation drives activation of the Src kinase
David E Heppner, Christopher M Dustin, Chenyi Liao, et al.
JCI Insight
|
November 5, 2016
DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma
Aida Habibovic, Milena Hristova, David E Heppner, et al.
Nature Communications
|
May 9, 2022
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
Tyler S Beyett, Ciric To, David E Heppner, et al.
Redox Biology
|
February 9, 2019
Lung epithelial protein disulfide isomerase A3 (PDIA3) plays an important role in influenza infection, inflammation, and airway mechanics
Nicolas Chamberlain, Bethany R Korwin-Mihavics, Emily M Nakada, et al.
Scientific Reports
|
March 21, 2019
Dysregulated Redox Regulation Contributes to Nuclear EGFR Localization and Pathogenicity in Lung Cancer
Andrew C Little, Milena Hristova, Loes van Lith, et al.
Journal of Medicinal Chemistry
|
June 20, 2025
Enhancing Selectivity and Potency of S<sub>N</sub>Ar Covalent Inhibitors of NADPH Oxidase Enzymes
Blessing C Ogboo, Kishan B Patel, Marta Massari, et al.
ACS Medicinal Chemistry Letters
|
November 22, 2019
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors
Dries J H De Clercq, David E Heppner, Ciric To, et al.
ACS Medicinal Chemistry Letters
|
December 15, 2022
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
David E Heppner, Florian Wittlinger, Tyler S Beyett, et al.
Page
of 6